Oral Minoxidil and Sexual Function: What the Evidence Actually Shows

What the safety data show

The largest dataset is a retrospective multicentre study of 1,404 patients (943 women, 461 men, mean age 43) treated with low-dose oral minoxidil for at least three months, with no control group. Hypertrichosis was the most frequent adverse effect at 15.1% and led to withdrawal in 14 patients (0.5%). Systemic effects were lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3% and insomnia 0.2%; 29 patients (1.2%) stopped treatment because of them, and no life-threatening effects were observed [1].

A review of 17 studies covering 634 patients concluded that oral minoxidil was effective and well tolerated in healthy patients who struggle with topical use, and that larger randomized dose-comparison studies were needed [6].

The tablet label's adverse reactions section, which reflects antihypertensive doses, lists hypertrichosis in about 80% of patients, temporary edema in 7%, ECG T-wave changes in about 60%, breast tenderness in under 1%, rare rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis, and rare thrombocytopenia and leukopenia [2]. It also states that no endocrine abnormalities have been found to explain the abnormal hair growth, describing it as hypertrichosis without virilism [2].

Blood pressure and heart rate at hair-loss doses

A 2025 systematic review and meta-analysis of low-dose oral minoxidil at 5 mg per day or less, drawn from studies without control groups, found no significant change in systolic blood pressure (mean difference -0.13 mm Hg, 95% CI -2.67 to 2.41) or diastolic pressure (-1.25 mm Hg, 95% CI -3.21 to 0.71), and a significant rise in heart rate of 2.67 beats per minute (95% CI 0.34 to 5.01). Hypotensive symptoms were reported in 119 patients (5.0%) with no hypotensive episodes, and hypertrichosis accounted for 34.6% of discontinuations [5].

Minoxidil lowers blood pressure by direct arteriolar vasodilation, and the fall in pressure triggers reflex increases in heart rate and in salt and water retention, which is why the tablet label requires a beta blocker and a diuretic at antihypertensive doses [2]. The label also states that minoxidil does not interfere with vasomotor reflexes and therefore does not produce orthostatic hypotension [2].

Dose appears to matter for the cardiovascular signal. In a meta-regression of six studies in androgenetic alopecia, each extra 1 mg per day of low-dose oral minoxidil was associated at six months with 47.1 more hairs per cm2 of total hair density, a 17.9% higher risk of hypertrichosis and a 4.8% higher risk of cardiovascular adverse events; the authors describe these as associations from observational data, not causal findings [7].

The tablet's boxed warning (pericardial effusion, worsening angina, fluid retention) is written for antihypertensive doses [2]. Case reports describe pericardial effusion with low-dose use for hair loss, while a 2025 large retrospective cohort found no association. Fluid retention, tachycardia and lightheadedness do occur at low doses [1].

The one drug interaction the tablet label names

The label's drug interactions section refers only to guanethidine. The label says that combining minoxidil with guanethidine can cause profound orthostatic effects, that guanethidine should be stopped well before minoxidil is started if at all possible, and that otherwise minoxidil should be started in the hospital [2].

How this compares with finasteride

Finasteride has been associated with persistent sexual side effects. In a clinical series, 54 men who had developed persistent sexual side effects while taking finasteride were reassessed after 9 to 16 months (mean 14); persistent side effects were still present in 96%, and 89% met the Arizona Sexual Experience Scale definition of sexual dysfunction [8]. Those men were selected because they already had persistent symptoms, so the figures do not describe how often sexual side effects occur among finasteride users generally, and this is not a head-to-head comparison with minoxidil.

Off-label status

The tablet label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication, so hair-loss use is off-label at every dose [2]. The label describes minoxidil as a direct peripheral arteriolar vasodilator [2].